{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:39Z","timestamp":1791245199488,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a common hematologic malignancy characterized by clonal plasma cell proliferation. Despite significant therapeutic advancements with proteasome inhibitors, immunomodulatory drugs, and anti-B-cell maturation antigen (BCMA) therapies, the disease remains largely incurable. Immunoparesis, a severe state of immune dysfunction, exhibits high prevalence in MM patients and profoundly impacts prognosis. This review summarizes the pathogenic mechanisms and clinical characteristics of immunoparalysis, with a focus on its impact on prognosis and early-onset infections, the effects of contemporary drug therapies on immunoparalysis, and immune reconstitution.<\/jats:p>","DOI":"10.3389\/fonc.2025.1628144","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:32:08Z","timestamp":1758630728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunoparesis in multiple myeloma: a current overview"],"prefix":"10.3389","volume":"15","author":[{"given":"Hongfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2005","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(80)90097-5","article-title":"Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosis","volume":"17","author":"Pruzanski","year":"1980","journal-title":"Clin Immunol Immunopathology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16488","article-title":"Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma","volume":"189","author":"Chakraborty","year":"2020","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092278","article-title":"Clinical considerations for immunoparesis in multiple myeloma","volume":"14","author":"Chahin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14026","article-title":"Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients","volume":"174","author":"Harutyunyan","year":"2016","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158345","article-title":"Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma","volume":"102","author":"Gonz\u00e1lez-Calle","year":"2017","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999939","article-title":"The role of the bone microenvironment in regulating myeloma residual disease and treatment","volume":"12","author":"Dadzie","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-021-01380-0","article-title":"CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma","volume":"20","author":"Gu","year":"2021","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41392-021-00746-6","article-title":"BUB1B and circBUB1B_544aa aggravate multiple myeloma Malignancy through evoking chromosomal instability","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200354","article-title":"Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target","volume":"36","author":"Luo","year":"2022","journal-title":"FASEB J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.11.020","article-title":"Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments","volume":"414","author":"Hu","year":"2018","journal-title":"Cancer Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153574","article-title":"Blockage of the JAK\/STAT3 signaling pathway in multiple myeloma by leelamine","volume":"87","author":"Jung","year":"2021","journal-title":"Phytomedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.146","article-title":"Pathogenesis and treatment of multiple myeloma","volume":"3","author":"Yang","year":"2022","journal-title":"MedComm (2020)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.909880","article-title":"Multiple myeloma-derived extracellular vesicles modulate the bone marrow immune microenvironment","volume":"13","author":"Lopes","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol BioMed"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117503","article-title":"IGF-1 promotes multiple myeloma progression through PI3K\/Akt-mediated epithelial-mesenchymal transition","volume":"249","author":"Peng","year":"2020","journal-title":"Life Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1038\/bcj.2017.46","article-title":"Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma","volume":"7","author":"Ravi","year":"2017","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.1.129","article-title":"Baff binds to the tumor necrosis factor receptor\u2013like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329378","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"29","author":"Chen","year":"2024","journal-title":"Hematology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.008","article-title":"Impact of etiological cytogenetic abnormalities on the depth of immunoparesis and survival in newly diagnosed multiple myeloma","volume":"22","author":"Caro","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.23355","article-title":"Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age","volume":"88","author":"Cherry","year":"2013","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111277","article-title":"Development of a nomogram prognostic model for early Grade \u2265 3 infection in newly diagnosed multiple myeloma based on immunoparesis","volume":"126","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B40","article-title":"Suppression of polyclonal immunoglobulin production by M-proteins shows isotype specificity","volume":"31","author":"Wang","year":"2001","journal-title":"Ann Clin Lab Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (Asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"Blad\u00e9","year":"2010","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284662","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1855345","article-title":"Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients","volume":"62","author":"Geng","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3574-4","article-title":"Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population","volume":"12","author":"S\u00f8rrig","year":"2017","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194978","article-title":"Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Pozzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23932","article-title":"Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database","volume":"90","author":"Holmstr\u00f6m","year":"","journal-title":"Am J Hematol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1088647","article-title":"Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past","volume":"57","author":"de la Rubia","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1973.03650100076014","article-title":"Infections complicating multiple myeloma and chronic lymphocytic leukemia","volume":"132","author":"Twomey","year":"1973","journal-title":"Arch Intern Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.579","article-title":"Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma","volume":"98","author":"Porrata","year":"2001","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04068-5","article-title":"Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma","volume":"99","author":"Eisfeld","year":"2020","journal-title":"Ann Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18182","article-title":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","volume":"198","author":"D\u00e1vila","year":"2022","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-0035-4","article-title":"Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells","volume":"22","author":"Shen","year":"2016","journal-title":"Pathol Oncol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628144\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:32:09Z","timestamp":1758630729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628144\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":68,"alternative-id":["10.3389\/fonc.2025.1628144"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1628144","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1628144"}}